Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-06-05
2007-06-05
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388200, C435S326000, C435S332000, C435S336000
Reexamination Certificate
active
10441728
ABSTRACT:
The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5008196 (1991-04-01), Connolly et al.
patent: 5036003 (1991-07-01), Olander et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5283354 (1994-02-01), Lemischka
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5840301 (1998-11-01), Rockwell et al.
patent: 5861499 (1999-01-01), Rockwell et al.
patent: 5874542 (1999-02-01), Rockwell et al.
patent: 5955311 (1999-09-01), Rockwell et al.
patent: 6365157 (2002-04-01), Rockwell et al.
patent: 6448077 (2002-09-01), Rockwell et al.
patent: 6811779 (2004-11-01), Rockwell et al.
patent: 0370989 (1990-05-01), None
patent: 0666868 (1995-08-01), None
patent: 370989 (1996-09-01), None
patent: 484401 (1996-09-01), None
patent: WO 90/13649 (1990-11-01), None
patent: WO 91/00916 (1991-01-01), None
patent: WO 91/02058 (1991-02-01), None
patent: WO 92/14748 (1992-09-01), None
patent: WO 93/07270 (1993-04-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/14748 (1994-07-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO 2005/044853 (2005-05-01), None
Leung et al. Science 246: 1306-1309 (1989).
Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, New York 1988, pp. 23-35.
Reilly et al. Biochem. Biophys. Res. Commun. 164: 736-743, 1989.
Dvorak et al., “Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels”Journal of Experimental Medicine174:1275-1278 (1991).
Hori et al., “Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor”Cancer Research51(22):6180-6184 (Nov. 15, 1991).
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo”Nature362:841-844 (1993).
Kim et al., “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies”Growth Factorsλ(1):53-64 (1992).
Klagsbrun and D'Amore, “Regulators of angiogenesis”Ann. Rev. Physiol.53:217-239 (1991).
Takahashi et al., “Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor”Federation of European Biochemical Societies288:65-71 (1991).
Adamis et al., “Increased Vascular Endothelial Growth Factor Levels in the Vitreous of”American Journal of Ophthalmology118:445-450 (1994).
Baird et al., “Immunoreactive Fibroblast Growth Factor (FGF) in a Transplantable Chondrosarcoma: Inhibition of Tumor Growth by Antibodiees to FGF”J. Cell. Biochem.30:79-85 (1986).
Barinaga, M., “Designing Therapies That Target Tumor Blood Vessel”Science275:482-484 (1997).
Ben-Efraim, “Cancer Immunotherapy: Hopes and Pitfalls: A Review”Anticancer Research16:3235-3240 (1996).
Dennis and Rifkin, “Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumor growth”J. Cellular Physiology144:84-98 (1990).
Hillan KJ, et al., “The role of VEGF expression in response to Bevacizumab plus capecitabine in metastatic breast cancer (MBC)”Proc Am Soc Clin Oncol22:191 (2003).
Kuntz, “Structure-Based Strategies for Drug Design and Discovery”Science257:1078-1081 (1992).
Shibuya, “Role of VEGF-FLT Receptor System in Normal and Tumor Angiogenesis”Advances in Cancer Research67:281-316 (1995).
Abuchowski et al., “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase”Journal of Biological Chemistry252(11):3582-3586 (Jun. 1977).
Adamis et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate”Arch. Ophthalmology114(1):66-71 (1996).
Aiello et al., “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGP- receptor chimeric proteins”Proc. Natl. Acad. Sci.92(23):10457-10461 (1995).
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders”New England J. of Medicine331(22):1480-1487 (1994).
Aruffo et al., “CD44 is the Principal Cell Surface Receptor for Hyaluronate”Cell61:1303-1313 (1990).
Ashkenazi et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin”Proc. Natl. Acad. Sci.88:10535-10539 (1991).
Bennett et al., “Extracellular Domain-IgG Fusion Proteins for Three Human Natriuretic Peptide Receptors. Hormone Pharmacology and Application to Solid Phase Screening of Synthetic Peptide Antisera”The Journal of Biological Chemistry266(34):23060-23067 (1991).
Benson et al., “Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200” Proceedings of the American Society of Clinical Oncology 22(243):975 (2003).
Burstein HJ, et al., “Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer”25th Annual San Antonio Breast Cancer Symposium(2002).
Burstein HJ, et al., “Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer.”Breast Cancer Res Treat76:S115 (2002).
Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy”Nature337:525-531 (1989).
Carson WE, et al., “A phase 2 trial of a recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma”Proc Am Soc Clin Oncol22:705 (2003).
Chen et al., “Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301)”American Society of Clinical Oncology Meeting Proceedings(Abstract #3515) 23 (2004).
Chen, H., “Expanding the Clinical Development of Bevacizumab”The Oncologist9(suppl 1):27-35 (2004).
Cobleigh MA, et al., “A Phase I/II dose-escalation trial of bevecizumab in previously treated metastatic breast cancer”Semin Oncol30(suppl 16):117-124 (2003).
Connolly et al., “Human Vascular Permeability Factor”Journal of Biological Chemistry264(33):20017-20024 (1989).
Crane CH, et al., “Preliminary results of a phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP)”1st annual Gastrointestinal Cancers Symposium(San Francisco, California) (Jan. 22, 2004).
Crane CH, et al., “Preliminary results of a phase I study of rhumba VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP) in locally advanced pancreatic cancer”Eur J Cancer Suppl1:S294 (2003).
D'Adamo DR, e
Cui Steven X.
Gambel Phillip
Genentech Inc.
Genentech, Inc.
LandOfFree
Antibodies to vascular endothelial cell growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to vascular endothelial cell growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to vascular endothelial cell growth factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3883009